Midostaurin, also known as Rydapt and under the chemical name [6R-6α,7β,8β,9α)-7-methoxy-6-(6-methoxy-2H-pyran-3-ylmethyl)-6,7,8,9-tetrahydro-5H-pyrimido[1,6-a]pyrazin-4-yl]amine, is a new drug used to treat acute myeloid leukemia (AML) and systemic mastocytosis (SM). Midostaurin is a potent oral multikinase inhibitor targeting multiple tyrosine kinases associated with cancer, including FLT3-ITD, KIT, and protein kinase C. A number of clinical trials have demonstrated the effectiveness of midostaurin therapy in treating various types of cancer.
Chemical Name
The Chemical name for Midostaurin is [6R-6α,7β,8β,9α)-7-methoxy-6-(6-methoxy-2H-pyran-3-ylmethyl)-6,7,8,9-tetrahydro-5H-pyrimido[1,6-a]pyrazin-4-yl]amine.
Molecular Formula
The molecular formula for Midostaurin is C35H30N4O4.
Formula Weight
The formula weight for Midostaurin is 570.65 g/mol.
CAS No
The CAS number for midostaurin is 320685-11-2.
Top Ten Keywords from Google and Synonyms
Health Benefits of Midostaurin
Midostaurin provides a number of health benefits for those who suffer from acute myeloid leukemia, systemic mastocytosis, and other cancers. It has been seen to help in reducing cancer cells in the body, preventing the growth of leukemia cells, and improving overall survival rates. In clinical trials, patients experienced improved responses when given midostaurin in combination with other chemotherapy drugs. It has also been shown to be effective in treating myelofibrosis, a bone marrow disorder that can lead to anemia and other complications.
Potential Effects
Midostaurin is a multikinase inhibitor that works by inhibiting a number of kinases important in the growth and survival of cancer cells. The main function of midostaurin is to inhibit the activity of the FLT3 receptor tyrosine kinase, which plays a key role in the development of acute myeloid leukemia. Midostaurin also inhibits the KIT receptor tyrosine kinase, which is important in the growth and survival of cancer cells. Additionally, midostaurin inhibits the activity of protein kinase C, which has been implicated in the development of certain malignancies.
Product Mechanism
Midostaurin works by inhibiting kinase pathways targeted in the proliferation of cancer cells. It targets multiple tyrosine kinases, such as FLT3-ITD, KIT, and protein kinase C to reduce the growth of cancer cells in the body. FLT3-ITD is a mutation commonly found in acute myeloid leukemia patients which contributes to the development and progression of their condition.
